Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), is set to participate in the 43rd Annual Cowen Healthcare Conference on March 6, 2023, at 1:30 p.m. ET in Boston. CEO Douglas Love will engage in a fireside chat during the event. Interested parties can access the live webcast on Annexon's Investors page, with a replay available for 30 days post-event. Annexon focuses on creating innovative complement medicines aimed at treating autoimmune, neurodegenerative, and ophthalmic disorders, and is advancing a diversified pipeline with clinical data expected in 2023 and beyond.
- None.
- None.
BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 43rd Annual Cowen Healthcare Conference on Monday, March 6, 2023 at 1:30 p.m. ET in Boston.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company seeking to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathway components that contribute to disease, while selectively preserving the beneficial immune functions of other complement pathways. Annexon is rigorously developing a pipeline of diversified product candidates across multiple mid- to late-stage clinical trials, with clinical data anticipated throughout 2023 and beyond.
Investor Contact:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
When will Annexon participate in the Cowen Healthcare Conference?
Who is the CEO of Annexon?
How can I access the webcast of the Annexon presentation?
What is Annexon focusing on in its research?
What ticker symbol is Annexon listed under?
